$599

New Pfizer Oral GLP-1RA Compound in Ph1

A CT.gov record has been observed for a new Pfizer Ph1 study evaluating multiple escalating oral doses of a novel compound PF-07081532 in T2DM patients and non-T2DM patients with obesity. Below, FENIX provides thoughts on this new trial in the context of oral GLP-1RA pipeline candidates from Pfizer and others.

This content is for Read Less members only.
Register
Already a member? Log in here